Abstract: The present invention relates to the field of biomedicine, specifically to a monoclonal antibody targeting SIRP?, and a preparation method and the use thereof. The SIRP? antibody or the antigen-binding portion thereof prepared by the present invention has a high affinity for SIRP? and a low affinity for SIRP?, which differ by two orders of magnitude. The SIRP? antibody or the antigen-binding portion thereof can efficiently block the binding of CD47 to SIRP?-V1, SIRP?-V2 and SIRP?-V8, thereby promoting the activation of macrophages, particularly enhancing the regulatory antibody-dependent cellular phagocytosis (ADCP) of a target tumor cell, bridging about innate and adaptive immune responses, and promoting the synergistic anti-cancer effect of the SIRP? antibody or the antigen-binding portion thereof with a checkpoint inhibitor PD-(L)1 monoclonal antibody. The antibody can be used for treating various cancers and microbial infectious diseases.

Abstract: The present invention discloses a pharmaceutical composition comprising GLP-1 analogs. In one embodiment, the composition further comprises buffers, stabilizers, isotonic agents, preservatives, or a mixture thereof. The present invention has the advantage of providing a highly stabilized pharmaceutical formulation of a GLP-1 analog suitable for long-term shelf-life and distribution in the commercial pharmaceutical supply chain. The disclosed formulations effectively protect the active ingredient GLP-1 analogs from degradation, oxidation, precipitation, crystallization, and other factors leading to loss of clinical efficacy.

Abstract: The present invention provides a pharmaceutical formulation containing a recombinant human serum albumin-interferon ? fusion protein (rHSA-IFN?), said formulation is prepared by dissolving the fusion protein and a pharmaceutically acceptable stable excipient in a pharmaceutically acceptable buffer which pH ranges from 5.0 to 8.0. The recombinant human serum albumin-interferon ? fusion protein concentration ranges from 0.1 mg/ml to 5 mg/ml. The stable excipient is glycine or methionine. The pharmaceutical formulation containing rHSA-IFN? has storage stability, which could act as immunomodulators for the treatment of viral infectious diseases, tumors and related diseases in the route of subcutaneous or intravenous administration.